Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Non Operating Investment Income (2017 - 2025)

Historic Non Operating Investment Income for Ligand Pharmaceuticals (LGND) over the last 9 years, with Q3 2025 value amounting to $7.8 million.

  • Ligand Pharmaceuticals' Non Operating Investment Income rose 22397.17% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$27.5 million, marking a year-over-year decrease of 12394.91%. This contributed to the annual value of $75.0 million for FY2024, which is 6181.17% up from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' Non Operating Investment Income stood at $7.8 million, which was up 22397.17% from $939000.0 recorded in Q2 2025.
  • Ligand Pharmaceuticals' Non Operating Investment Income's 5-year high stood at $110.8 million during Q1 2024, with a 5-year trough of -$23.9 million in Q4 2024.
  • In the last 5 years, Ligand Pharmaceuticals' Non Operating Investment Income had a median value of $939000.0 in 2025 and averaged $7.4 million.
  • Its Non Operating Investment Income has fluctuated over the past 5 years, first crashed by 648000.0% in 2021, then skyrocketed by 43026.57% in 2022.
  • Over the past 5 years, Ligand Pharmaceuticals' Non Operating Investment Income (Quarter) stood at -$13.4 million in 2021, then skyrocketed by 430.27% to $44.2 million in 2022, then crashed by 63.78% to $16.0 million in 2023, then plummeted by 249.14% to -$23.9 million in 2024, then skyrocketed by 132.63% to $7.8 million in 2025.
  • Its Non Operating Investment Income was $7.8 million in Q3 2025, compared to $939000.0 in Q2 2025 and -$12.4 million in Q1 2025.